G1 Therapeutics, Inc.
Symbool: GTHX
NASDAQ
4.44
USDMarktprijs vandaag
-7.4160
Koers/Winst Verhouding
-0.3307
Koers/Winst Groei Verhouding
232.23M
MRK Kapitalisatie
- 0.00%
DIV Rendement
G1 Therapeutics, Inc. (GTHX) Jaarrekeningen
Balans
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 345.99 | 82.2 | 145.1 | 221.2 | ||||||||||
balance-sheet.row.short-term-investments | 185.28 | 49.9 | 50.5 | 0 | ||||||||||
balance-sheet.row.net-receivables | 46.78 | 12.7 | 11.1 | 5.7 | ||||||||||
balance-sheet.row.inventory | 54.08 | 12.4 | 16.2 | 3.5 | ||||||||||
balance-sheet.row.other-current-assets | 30.42 | 7.6 | 7.1 | 13.2 | ||||||||||
balance-sheet.row.total-current-assets | 477.33 | 114.9 | 179.5 | 243.6 | ||||||||||
balance-sheet.row.property-plant-equipment-net | 26.32 | 6.4 | 8 | 9 | ||||||||||
balance-sheet.row.goodwill | 0 | 0 | 0 | 0 | ||||||||||
balance-sheet.row.intangible-assets | 0 | 0 | 0 | 0 | ||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 0 | 0 | 0 | 0 | ||||||||||
balance-sheet.row.long-term-investments | 0.62 | 0.2 | 0.3 | 0.3 | ||||||||||
balance-sheet.row.tax-assets | 0 | 0 | 0 | 0 | ||||||||||
balance-sheet.row.other-non-current-assets | 0.28 | 0 | 0.3 | 1.2 | ||||||||||
balance-sheet.row.total-non-current-assets | 27.23 | 6.6 | 8.5 | 10.5 | ||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | ||||||||||
balance-sheet.row.total-assets | 504.55 | 121.5 | 188 | 254.1 | ||||||||||
balance-sheet.row.account-payables | 22.2 | 4 | 7.4 | 2.9 | ||||||||||
balance-sheet.row.short-term-debt | 31.9 | 1.3 | 1.1 | 1.1 | ||||||||||
balance-sheet.row.tax-payables | 0 | 0 | 0 | 0 | ||||||||||
balance-sheet.row.long-term-debt-total | 116.16 | 51.6 | 82.6 | 81.9 | ||||||||||
Deferred Revenue Non Current | 2 | 0.5 | 1 | 1 | ||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | -46.6 | - | - | - | ||||||||||
balance-sheet.row.other-current-liab | 73.94 | 23.8 | 27 | 23.6 | ||||||||||
balance-sheet.row.total-non-current-liabilities | 210.97 | 56.4 | 83.6 | 82.9 | ||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | ||||||||||
balance-sheet.row.capital-lease-obligations | 18.01 | 4.3 | 6.8 | 7.9 | ||||||||||
balance-sheet.row.total-liab | 340.86 | 86.2 | 119.2 | 110.6 | ||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | ||||||||||
balance-sheet.row.common-stock | 0.02 | 0 | 0 | 0 | ||||||||||
balance-sheet.row.retained-earnings | -3090.2 | -780 | -732 | -584.5 | ||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 0 | 0 | 0 | 0 | ||||||||||
balance-sheet.row.other-total-stockholders-equity | 2441.74 | 815.4 | 800.8 | 0 | ||||||||||
balance-sheet.row.total-stockholders-equity | -648.43 | 35.4 | 68.7 | -584.5 | ||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | -307.57 | 121.5 | 188 | -473.9 | ||||||||||
balance-sheet.row.minority-interest | 0 | 0 | 0 | 0 | ||||||||||
balance-sheet.row.total-equity | -648.43 | 35.4 | 68.7 | -584.5 | ||||||||||
balance-sheet.row.total-liabilities-and-total-equity | -307.57 | - | - | - | ||||||||||
Total Investments | 185.47 | 50.1 | 50.5 | 0.3 | ||||||||||
balance-sheet.row.total-debt | 127.72 | 57.2 | 83.8 | 83.1 | ||||||||||
balance-sheet.row.net-debt | -74.71 | 24.9 | -10.8 | -138.1 |
Kasstroomoverzicht
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | -30.59 | -48 | -147.6 | -148.4 | ||||||||||
cash-flows.row.depreciation-and-amortization | 0.5 | 0.5 | 0.5 | 0.5 | ||||||||||
cash-flows.row.deferred-income-tax | 0 | 1.2 | 0 | 0.6 | ||||||||||
cash-flows.row.stock-based-compensation | 10.67 | 14.5 | 20.6 | 22.3 | ||||||||||
cash-flows.row.change-in-working-capital | 1.14 | -5.2 | -5.3 | -8.8 | ||||||||||
cash-flows.row.account-receivables | 4.37 | -1.6 | -5.4 | -5.5 | ||||||||||
cash-flows.row.inventory | 3 | 3.7 | -12.7 | -3.5 | ||||||||||
cash-flows.row.account-payables | -0.37 | -3.4 | 4.4 | -0.7 | ||||||||||
cash-flows.row.other-working-capital | -4.26 | -4 | 8.4 | 0.8 | ||||||||||
cash-flows.row.other-non-cash-items | 9.12 | -1.4 | 3.1 | 1.7 | ||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | -18.18 | 0 | 0 | 0 | ||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | 0 | 0 | -0.5 | 0 | ||||||||||
cash-flows.row.acquisitions-net | 0 | 0 | 50 | 0 | ||||||||||
cash-flows.row.purchases-of-investments | -116.81 | -124.7 | -65 | 0 | ||||||||||
cash-flows.row.sales-maturities-of-investments | 122 | 127.5 | 15 | 0 | ||||||||||
cash-flows.row.other-investing-activites | -0.1 | 0 | -50 | 0 | ||||||||||
cash-flows.row.net-cash-used-for-investing-activites | 5.19 | 2.8 | -50.5 | 0 | ||||||||||
cash-flows.row.debt-repayment | -26.69 | -26.7 | 0 | -53.6 | ||||||||||
cash-flows.row.common-stock-issued | -0.01 | -0.2 | 52.4 | 86.4 | ||||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | 0 | 0 | ||||||||||
cash-flows.row.dividends-paid | 0 | 0 | 0 | 0 | ||||||||||
cash-flows.row.other-financing-activites | -8.76 | -0.3 | 0.1 | 113.1 | ||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | -35.42 | -26.9 | 52.5 | 145.9 | ||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | 0.1 | 0 | 0 | ||||||||||
cash-flows.row.net-change-in-cash | -48.41 | -62.4 | -126.7 | 13.8 | ||||||||||
cash-flows.row.cash-at-end-of-period | 161.52 | 32.3 | 94.9 | 221.6 | ||||||||||
cash-flows.row.cash-at-beginning-of-period | 209.93 | 94.7 | 221.6 | 207.8 | ||||||||||
cash-flows.row.operating-cash-flow | -18.18 | -38.3 | -128.6 | -132.1 | ||||||||||
cash-flows.row.capital-expenditure | 0 | 0 | -0.5 | 0 | ||||||||||
cash-flows.row.free-cash-flow | -18.18 | -38.3 | -129.1 | -132.1 |
Rij winst-en-verliesrekening
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 84.04 | 82.5 | 51.3 | 31.5 | ||||||||||
income-statement-row.row.cost-of-revenue | 6.82 | 7.2 | 3.7 | 2 | ||||||||||
income-statement-row.row.gross-profit | 77.23 | 75.3 | 47.6 | 29.5 | ||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | ||||||||||
income-statement-row.row.research-development | 35.55 | - | - | - | ||||||||||
income-statement-row.row.selling-general-administrative | 0 | - | - | - | ||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | ||||||||||
income-statement-row.row.other-expenses | 5.27 | 2.2 | 0 | -0.3 | ||||||||||
income-statement-row.row.operating-expenses | 102.6 | 114.8 | 183.7 | 171.9 | ||||||||||
income-statement-row.row.cost-and-expenses | 106.34 | 122 | 187.5 | 173.9 | ||||||||||
income-statement-row.row.interest-income | 2.04 | 2.5 | 0.7 | 0 | ||||||||||
income-statement-row.row.interest-expense | 0.74 | 10 | 10.4 | 4.7 | ||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | ||||||||||
income-statement-row.row.total-other-income-expensenet | -2.58 | -5.3 | -9.7 | -5 | ||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | ||||||||||
income-statement-row.row.other-operating-expenses | 5.27 | 2.2 | 0 | -0.3 | ||||||||||
income-statement-row.row.total-operating-expenses | -2.58 | -5.3 | -9.7 | -5 | ||||||||||
income-statement-row.row.interest-expense | 0.74 | 10 | 10.4 | 4.7 | ||||||||||
income-statement-row.row.depreciation-and-amortization | 0.51 | 0.5 | 1.3 | -0.3 | ||||||||||
income-statement-row.row.ebitda-caps | -21.23 | - | - | - | ||||||||||
income-statement-row.row.operating-income | -22.83 | -39.5 | -136.2 | -142.5 | ||||||||||
income-statement-row.row.income-before-tax | -27.48 | -44.9 | -145.9 | -147.4 | ||||||||||
income-statement-row.row.income-tax-expense | 3.12 | 3.1 | 1.7 | 0.9 | ||||||||||
income-statement-row.row.net-income | -30.59 | -48 | -147.6 | -148.4 |
Vaak gestelde vragen
Wat is G1 Therapeutics, Inc. (GTHX) totale activa?
G1 Therapeutics, Inc. (GTHX) totale activa is 121540000.000.
Wat is de jaarlijkse omzet van de onderneming?
De jaarlijkse omzet is 29349000.000.
Wat is de winstmarge van de onderneming?
De bedrijfswinstmarge is 0.919.
Wat is vrije kasstroom van de onderneming?
De vrije kasstroom is {free_cash_flow}}.
Wat is de nettowinstmarge van de onderneming?
De nettowinstmarge is -0.364.
Wat is de totale omzet van de onderneming?
De totale opbrengst is -0.272.
Wat is G1 Therapeutics, Inc. (GTHX) nettowinst (netto-inkomen)?
De nettowinst is -47967000.000.
Wat is de totale schuld van het bedrijf?
De totale schuld is 57173000.000.
Wat zijn de bedrijfskosten?
De bedrijfsuitgaven zijn 114843000.000.
Wat is het kasstroomcijfer van het bedrijf?
Enretprise cash is 19887000.000.